Background
Literature review with illustrative case reports of the most frequent hematologic irAEs: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cell aplasia (PRCA). PubMed search through latest literature plus institutional case series.
Interventions and follow up
Design: Literature review and illustrative case series of hematologic irAEs (AIHA, ITP, PRCA) from immune checkpoint inhibitors
Primary endpoint: Synthesis of presentation, management, and outcomes
mFollow up: Variable; median 6-12 months across cases
Primary endpoint: Synthesis of presentation, management, and outcomes
mFollow up: Variable; median 6-12 months across cases
Results
Onset: AIHA/ITP median ~3 cycles (~3 months); PRCA ~4 cycles
First-line response: most achieved remission with corticosteroid monotherapy (prednisolone 1-2 mg/kg/day, tapered)
Steroid-refractory/relapsed: 10-15%, requiring second-line immunosuppressants (mycophenolate mofetil, cyclosporine, IVIG, rituximab)
ICI rechallenge: controversial; recurrence rates 20-50%; feasible in selected patients in complete remission with supportive management in place
First-line response: most achieved remission with corticosteroid monotherapy (prednisolone 1-2 mg/kg/day, tapered)
Steroid-refractory/relapsed: 10-15%, requiring second-line immunosuppressants (mycophenolate mofetil, cyclosporine, IVIG, rituximab)
ICI rechallenge: controversial; recurrence rates 20-50%; feasible in selected patients in complete remission with supportive management in place
Adverse events
AIHA: hemoglobinuria, jaundice, LDH elevation, reticulocytosis
ITP: petechiae, mucosal bleeding, platelet <20,000/μL
PRCA: severe anemia, reticulocytopenia
Diagnostic workup: direct antiglobulin test (AIHA), bone marrow biopsy (PRCA), exclusion of other causes (infections, splenomegaly, medications)
ITP: petechiae, mucosal bleeding, platelet <20,000/μL
PRCA: severe anemia, reticulocytopenia
Diagnostic workup: direct antiglobulin test (AIHA), bone marrow biopsy (PRCA), exclusion of other causes (infections, splenomegaly, medications)
Conclusions
Prompt recognition and management of hematologic irAEs is critical to minimize morbidity, preserve ICI efficacy, and avoid premature discontinuation. Increased clinician awareness, standardized diagnostic algorithms, and early hematology consultation are essential. Corticosteroid-based initial management is effective in the majority; second-line agents improve outcomes in refractory cases.
Key Limitations
Narrative review and case series, not a systematic review or controlled study; selection/publication bias; rare events with no incidence denominators; management recommendations based on low-level evidence; recurrence and rechallenge data heterogeneous.
Clinical Context
Practical reference for managing hematologic irAEs. Aligns with ASCO/ESMO irAE management frameworks: corticosteroids first-line, escalation to second-line immunosuppression (MMF, cyclosporine, IVIG, rituximab) for refractory disease, and individualized, cautious ICI rechallenge in selected patients.